MedTrace Logo

EPAT: Estrogen in the Prevention of Atherosclerosis Trial

NCT00115024 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2009-12-11

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).

Conditions

Interventions

DRUG

Micronized 17B-estradiol

Sponsors & Collaborators

  • Mead Johnson Nutrition

    collaborator INDUSTRY

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Howard N. Hodis, MD · University of Southern California, Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
46 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1994-04-30
Primary Completion
1998-11-30
Completion
1998-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00115024 on ClinicalTrials.gov